Academic Journal

The role of echocardiography in management of patients with hypertrophic cardiomyopathy (review) ; Роль эхокардиографии в ведении пациентов с гипертрофической кардиомиопатией (обзор литературы)

التفاصيل البيبلوغرافية
العنوان: The role of echocardiography in management of patients with hypertrophic cardiomyopathy (review) ; Роль эхокардиографии в ведении пациентов с гипертрофической кардиомиопатией (обзор литературы)
المؤلفون: G. G. Taradin, G. A. Ignatenko, I. V. Rakitskaya, Г. Г. Тарадин, Г. А. Игнатенко, И. В. Ракитская
المصدر: Meditsinskiy sovet = Medical Council; № 16 (2023); 128-136 ; Медицинский Совет; № 16 (2023); 128-136 ; 2658-5790 ; 2079-701X
بيانات النشر: REMEDIUM GROUP Ltd.
سنة النشر: 2023
المجموعة: Medical Council (E-Journal) / Медицинский Совет
مصطلحات موضوعية: обструкция, myocardial hypertrophy, phenotypic variants, imaging, diagnosis, obstruction, гипертрофия миокарда, фенотипические варианты, визуализация, диагностика
الوصف: The presented contains the discussion about the role of echocardiography in management of patients with hypertrophic cardiomyopathy (HCM). The article provides general information about the role of echocardiography in the diagnosis of the disease, clarification of the specific etiology of hypertrophy and differential diagnosis with secondary hypertrophy and phenocopies of HCMP. The features of right and left ventricular (LV) hypertrophy, determination of its predominant localization, phenotype, and conventionally used parameters for assessing myocardial hypertrophy, including the maximum LV wall thickness, LV myocardial mass and LV myocardial mass index, are discussed in detail. Knowledge of phenotypic variants helps to diagnose HCMP, to differentiated approach the management of patients and to choose the optimal treatment strategy. Special attention is paid to the assessment of the structure and function of the mitral valve (MV), the subvalvular apparatus and the phenomenon of systolic anterior motion of the MV responsible for the development of obstruction of the LV outflow tract. The previously existing opinion that cardiac abnormality in HCMP is limited only by hypertrophy of ventricular myocardium has recently undergone changes. Approximately 60% of patients with HCMP have at least one MV anomaly as a direct consequence of genetic mutations. The most common abnormalities that can be detected with echocardiography include elongation of the valvular leaflets and chords, prolapse of the valvular leaflets, hypertrophy, disposition and change in the number of papillary muscles. The importance and significance of assessing LV systolic and diastolic functions using echocardiography is emphasized. The role of transesophageal echocardiography in visualization of hypertrophy features of the MV structure and in the perioperative period during surgical correction of hypertrophied septum and valvular defects is also discussed. ; Представленный обзор посвящен обсуждению роли эхокардиографии (ЭхоКГ) в ведении пациентов с ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: Russian
Relation: https://www.med-sovet.pro/jour/article/view/7809/6931; Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99. https://doi.org/10.1016/j.jacc.2014.05.003.; Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–1254. https://doi.org/10.1016/j.jacc.2015.01.019.; Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550–1555. https://doi.org/10.1016/j.amjcard.2014.01.435.; Mandeş L, Roşca M, Ciupercă D, Popescu BA. The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy. J Echocardiogr. 2020;18(3):137–148. https://doi.org/10.1007/s12574-020-00467-9.; Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–668. https://doi.org/10.1056/NEJMra1710575.; Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail. 2018;6(5):364–375. https://doi.org/10.1016/j.jchf.2018.02.010.; Ватутин НТ, Тарадин ГГ, Марон МС, Шевелек АН. Внезапная сердечная смерть у больных гипертрофической кардиомиопатией. Кардиология. 2016;(1):56–65. https://doi.org/10.18565/cardio.2016.1.56-65.; Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):3022–3055. https://doi.org/10.1016/j.jacc.2020.08.044.; Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-ofthe-Art Review. J Am Coll Cardiol. 2022;79(4):372–389. https://doi.org/10.1016/j.jacc.2021.12.002.; Ватутин НТ, Тарадин ГГ, Марон МС. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35–42. https://doi.org/10.15829/1560-4071-2014-5-35-42.; Lopes LR, Elliott PM. Hypertrophic cardiomyopathies. In: Fuster V, Harrington RA, Narula J, Eapen ZJ (eds.). Hurst’s the Heart. McGraw-Hill Education; 2017.; Haland TF, Edvardsen T. The role of echocardiography in management of hypertrophic cardiomyopathy. J Echocardiogr. 2020;18(2):77–85. https://doi.org/10.1007/s12574-019-00454-9.; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–2779. https://doi.org/10.1093/eurheartj/ehu284.; Габрусенко СА, Гудкова АЯ, Козиолова НА, Александрова СА, Берсенева МИ, Гордеев МЛ и др. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(5):4541. https://doi.org/10.15829/1560-4071-2021-4541.; Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022;35(6):533–569. https://doi.org/10.1016/j.echo.2022.03.012.; Caiati C, Stanca A, Lepera ME. Case report: Diagnosis of apical hypertrophic cardiomyopathy that escaped clinical and echocardiographic investigations for twenty years: Reasons and clinical implications. Front Cardiovasc Med. 2023;10:1157599. https://doi.org/10.3389/fcvm.2023.1157599.; Begg A, Dahiya G, Kyvernitakis A, Biederman RWW. The use of contrastenhanced transthoracic echocardiography for spiral-variant hypertrophic cardiomyopathy. Echocardiography. 2020;37(11):1873–1876. https://doi.org/10.1111/echo.14871.; Habib M, Hoss S, Rakowski H. Evaluation of hypertrophic cardiomyopathy: newer echo and MRI approaches. Curr Cardiol Rep. 2019;21(8):75. https://doi.org/10.1007/s11886-019-1173-1.; Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41(2):315–321. https://doi.org/10.1016/s0735-1097(02)02713-4.; Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–1785. https://doi.org/10.1056/NEJM200006153422403.; Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, Manning WJ. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293–1298. https://doi.org/10.1016/j.amjcard.2007.05.061.; Keramida K, Lazaros G, Nihoyannopoulos P. Right ventricular involvement in hypertrophic cardiomyopathy: Patterns and implications. Hellenic J Cardiol. 2020;61(1):3–8. https://doi.org/10.1016/j.hjc.2018.11.009.; Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983;2(3):437–444. https://doi.org/10.1016/s0735-1097(83)80269-1.; Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48(3):418–428. https://doi.org/10.1016/0002-9149(81)90068-0.; Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699–1708. https://doi.org/10.1016/0735-1097(95)00390-8.; Syed IS, Ommen SR, Breen JF, Tajik AJ. Hypertrophic cardiomyopathy: identification of morphological subtypes by echocardiography and cardiac magnetic resonance imaging. JACC Cardiovasc Imaging. 2008;1(3):377–379. https://doi.org/10.1016/j.jcmg.2008.02.008.; Maron BJ, Maron MS. The Remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: From M-Mode Echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9(7):858–872. https://doi.org/10.1016/j.jcmg.2016.05.003.; Parato VM, Antoncecchi V, Sozzi F, Marazia S, Zito A, Maiello M, Palmiero P. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30. https://doi.org/10.1186/s12947-016-0072-5.; Rakowski H, Hoss S, Williams LK. Echocardiography in the diagnosis and management of hypertrophic cardiomyopathy. Cardiol Clin. 2019;37(1):11–26. https://doi.org/10.1016/j.ccl.2018.09.001.; Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559–566. https://doi.org/10.1016/j.jacc.2008.04.047.; Hindieh W, Chan R, Rakowski H. Complementary role of echocardiography and cardiac magnetic resonance in hypertrophic cardiomyopathy. Curr Cardiol Rep. 2017;19(9):81. https://doi.org/10.1007/s11886-017-0897-z.; Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39. https://doi.org/10.1016/j.echo.2014.10.003.; Losi MA, Imbriaco M, Canciello G, Pacelli F, Di Nardo C, Lombardi R et al. Left ventricular mass in hypertrophic cardiomyopathy assessed by 2d-echocardiography: validation with magnetic resonance imaging. J Cardiovasc Transl Res. 2020;13(2):238–244. https://doi.org/10.1007/s12265-019-09911-3.; Losi MA, Nistri S, Galderisi M, Betocchi S, Cecchi F, Olivotto I et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8:7. https://doi.org/10.1186/1476-7120-8-7.; Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28(1):1–83. https://doi.org/10.1016/0033-0620(85)90024-6.; Spirito P, Maron BJ, Chiarella F, Bellotti P, Tramarin R, Pozzoli M, Vecchio C. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation. 1985;72(2):310–316. https://doi.org/10.1161/01.cir.72.2.310.; Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990;15(4):808–813. https://doi.org/10.1016/0735-1097(90)90278-w.; Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357(9254):420–424. https://doi.org/10.1016/S0140-6736(00)04005-8.; Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280. https://doi.org/10.1093/ehjci/jeu291.; Jain CC, Newman DB, Geske JB. Mitral valve disease in hypertrophic cardiomyopathy: evaluation and management. Curr Cardiol Rep. 2019;21(11):136. https://doi.org/10.1007/s11886-019-1231-8.; Sherrid MV, Adams DH. The mitral valve in hypertrophic cardiomyopathy: other side of the outflow tract. J Am Coll Cardiol. 2020;76(19):2248–2251. https://doi.org/10.1016/j.jacc.2020.09.580.; Ro R, Halpern D, Sahn DJ, Homel P, Arabadjian M, Lopresto C, Sherrid MV. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol. 2014;64(19):1984–1995. https://doi.org/10.1016/j.jacc.2014.04.090.; Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124(1):40–47. https://doi.org/10.1161/CIRCULATIONAHA.110.985812.; Sakellaropoulos S, Svab S, Mohammed M, Dimitra L, Mitsis A. The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review. Curr Probl Cardiol. 2021;46(3):100641. https://doi.org/10.1016/j.cpcardiol.2020.100641.; Guigui SA, Torres C, Escolar E, Mihos CG. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. J Thorac Dis. 2022;14(6):2309–2325. https://doi.org/10.21037/jtd-22-182.; Nishimura RA, Seggewiss H, Schaff HV. Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation. Circ Res. 2017;121(7):771–783. https://doi.org/10.1161/CIRCRESAHA.116.309348.; Williams LK, Frenneaux MP, Steeds RP. Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management. Eur J Echocardiogr. 2009;10(8):iii9–14. https://doi.org/10.1093/ejechocard/jep157.; Critoph CH, Pantazis A, Tome Esteban MT, Salazar-Mendiguchía J, Pagourelias ED, Moon JC, Elliott PM. The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Open Heart. 2014;1(1):e000176. https://doi.org/10.1136/openhrt-2014-000176.; Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(11):1374–1386. https://doi.org/10.1016/j.jcmg.2017.07.016.; Игнатенко ГА, Тарадин ГГ, Ватутин НТ, Калуга АА, Костямин ЮД. Фибрилляция предсердий при гипертрофической кардиомиопатии. Архивъ внутренней медицины. 2021;11(3):173–185. https://doi.org/10.20514/2226-6704-2021-11-3-173-185.; Yang WI, Shim CY, Kim YJ, Kim SA, Rhee SJ, Choi EY et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2009;22(12):1338–1343. https://doi.org/10.1016/j.echo.2009.09.016.; Roşca M, Popescu BA, Beladan CC, Călin A, Muraru D, Popa EC et al. Left atrial dysfunction as a correlate of heart failure symptoms in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2010;23(10):1090–1098. https://doi.org/10.1016/j.echo.2010.07.016.; Dominguez F, González-López E, Padron-Barthe L, Cavero MA, Garcia-Pavia P. Role of echocardiography in the diagnosis and management of hypertrophic cardiomyopathy. Heart. 2018;104(3):261–273. https://doi.org/10.1136/heartjnl-2016-310559.; Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C et al. Hypertrophic cardiomyopathy outcomes investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015;17(8):837–845. https://doi.org/10.1002/ejhf.316.; Alphonse P, Virk S, Collins J, Campbell T, Thomas SP, Semsarian C, Kumar S. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review. Clin Res Cardiol. 2021;110(4):544–554. https://doi.org/10.1007/s00392-020-01730-w.; Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: Insights from the SHaRe registry. Circulation. 2020;141(17):1371–1383. https://doi.org/10.1161/CIRCULATIONAHA.119.044366.; Qiao J, Zhao P, Lu J, Huang L, Ma X, Zhou X, Xia L. Diastolic dysfunction assessed by cardiac magnetic resonance imaging tissue tracking on normal-thickness wall segments in hypertrophic cardiomyopathy. BMC Med Imaging. 2023;23(1):7. https://doi.org/10.1186/s12880-022-00955-7.; Nampiaparampil RG, Swistel DG, Schlame M, Saric M, Sherrid MV. Intraoperative twoand three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2018;31(3):275–288. https://doi.org/10.1016/j.echo.2017.11.016.; Venieri E, Aggeli C, Anastasakis A, Sambatakou H, Stefanadis C, Tousoulis D. Mitral valve in hypertrophic cardiomyopathy: a three dimensional transesophageal study. Hellenic J Cardiol. 2021;62(1):29–34. https://doi.org/10.1016/j.hjc.2019.04.004.; https://www.med-sovet.pro/jour/article/view/7809
DOI: 10.21518/ms2023-265
الاتاحة: https://www.med-sovet.pro/jour/article/view/7809
https://doi.org/10.21518/ms2023-265
Rights: Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY- NC-ND), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work. ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License (CC BY- NC-ND), которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access).
رقم الانضمام: edsbas.5BAA650A
قاعدة البيانات: BASE